Subject(s)
Obsessive-Compulsive Disorder , Psoriasis , Humans , Obsessive-Compulsive Disorder/epidemiology , Obsessive-Compulsive Disorder/diagnosis , Psoriasis/psychology , Psoriasis/epidemiology , Psoriasis/complications , Case-Control Studies , Female , Male , Adult , Middle Aged , United States/epidemiology , Young Adult , Adolescent , AgedABSTRACT
Biologic therapies targeting tumor necrosis factor alpha (TNF-α) (infliximab, adalimumab, certolizumab, etanercept), the p40 subunit shared by IL-12 and IL-23 (ustekinumab), the p19 subunit of IL-23 (guselkumab, tildrakizumab, risankizumab), IL-17A (secukinumab, ixekizumab), IL-17-RA (brodalumab) and both IL-17A and IL-17F (bimekizumab) have revolutionized the treatment of psoriasis. In both the short and long term, risankizumab had highest Psoriasis Area and Severity Index 90 scores compared to other oral and injectable biologics. IL-23 inhibitors had lowest rates of short-term and long-term adverse events and most favorable long-term risk-benefit profile compared to IL-17, IL-12/23, and TNF-α inhibitors.
Subject(s)
Antibodies, Monoclonal, Humanized , Antibodies, Monoclonal , Biological Products , Psoriasis , Ustekinumab , Psoriasis/drug therapy , Humans , Biological Products/therapeutic use , Ustekinumab/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Antibodies, Monoclonal/therapeutic use , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Etanercept/therapeutic use , Adalimumab/therapeutic use , Infliximab/therapeutic use , Interleukin-17/antagonists & inhibitors , Dermatologic Agents/therapeutic use , Certolizumab Pegol/therapeutic use , Interleukin-23/antagonists & inhibitors , Interleukin-12/antagonists & inhibitorsSubject(s)
Dermatitis, Atopic , Feeding and Eating Disorders , Humans , Dermatitis, Atopic/epidemiology , Dermatitis, Atopic/complications , Cross-Sectional Studies , Female , Male , Adult , Adolescent , Feeding and Eating Disorders/epidemiology , Feeding and Eating Disorders/complications , Young Adult , United States/epidemiology , Child , Middle AgedABSTRACT
A patient had burning and pain in the mouth, reduced oral aperture, white-tan plaques on the oral mucosa, and thickened buccal mucosae bilaterally; biopsy of the lower labial mucosa showed subepithelial fibrosis. She had no history of cigarette smoking or use of chewing tobacco but had current and past history of chewing areca nuts. What is the diagnosis and what would you do next?
